Results 51 to 60 of about 1,117 (238)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro +11 more
wiley +1 more source
On increasing the developability of a trimmed NURBS surface
, 2004 Developable surfaces are desired in designing products manufactured from planar sheets. Trimmed non-uniform rational B-spline (NURBS) surface patches are widely adopted to represent 3D products in CAD/CAM. This paper presents a new method to increase the
Wang, Charlie C.L. +3 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke +4 more
wiley +1 more source
Molecules, 2023 In the quest to market increasingly safer and more potent biotherapeutic proteins, the concept of the multi-attribute method (MAM) has emerged from biopharmaceutical companies to boost the quality-by-design process development.
Claire I. Butré +8 more
doaj +1 more source
Developable mechanisms on developable surfaces
Science Robotics, 2019 Developable mechanisms are proposed as next-generation mechanical systems that can conform to and emerge from developable surfaces.
Todd G. Nelson +4 more
openaire +3 more sources
Developing Drugs For Developing Countries [PDF]
Health Affairs, 2006 Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S.
David B, Ridley +2 more
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook +6 more
wiley +1 more source
Developability and related properties of the generalized compact-open topology [PDF]
, 2009 Developability and related properties (like weak developability,Gd-diagonal, G*d-diagonal, submetrizability) of the generalized compact-open topology tC on partial continuous functions P with closed domains in X and values in Y are studied.
Zsilinszky, Laszlo +1 more
core
Developing biobanks in developing countries.
Journal of global health, 2011 We call for the development of human biobanks in developing countries and describe several examples from low income countries which are already building their own biobanks. Developing human biobanks in developing countries requires strengthening of the research capacity to use the new technologies, as well as a shift in research investment priorities ...
Igor Rudan +2 more
openaire +3 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási +14 more
wiley +1 more source